You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions

Article info

Article menu

Download PDFPDF

XML
Review
Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions

Authors

  • Marc Hilmi Department of Medical Oncology, Curie InstituteUniversity of Versailles Saint-Quentin Paris France PubMed articlesGoogle scholar articles
  • Cindy Neuzillet Department of Medical Oncology, Curie InstituteUniversity of Versailles Saint-Quentin Paris France PubMed articlesGoogle scholar articles
  • Julien Calderaro Department of PathologyHenri Mondor Hospital Créteil France IMRB-INSERM U955 Team 18 Créteil France Université Paris-Est-Créteil Créteil France PubMed articlesGoogle scholar articles
  • Fouad Lafdil IMRB-INSERM U955 Team 18 Créteil France Université Paris-Est-Créteil Créteil France Institut Universitaire de France Paris France PubMed articlesGoogle scholar articles
  • Jean-Michel Pawlotsky IMRB-INSERM U955 Team 18 Créteil France Université Paris-Est-Créteil Créteil France National Reference Center for Viral Hepatitis B, C and D, Department of VirologyHenri Mondor Hospital Créteil France PubMed articlesGoogle scholar articles
  • Benoit Rousseau IMRB-INSERM U955 Team 18 Créteil France Department of Medicine, Division of Solid Tumor OncologyMemorial Sloan Kettering Cancer Center New York NY USA PubMed articlesGoogle scholar articles
  1. ↵f +1 (646) 431-2420 ben.rousseau{at}gmail.com
View Full Text

Citation

Hilmi M, Neuzillet C, Calderaro J, et al
Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions
Journal for ImmunoTherapy of Cancer 2019;7:333. doi: 10.1186/s40425-019-0824-5

Publication history

  • Received June 17, 2019
  • Accepted November 13, 2019
  • First published November 29, 2019.
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.